Capricor Therapeutics is trading 5.53% up now at $10.12, but no new company-specific announcement clearly explains the August 31, 2026 move.
- Recent volatility followed the FDA’s August 24 extension of Deramiocel’s PDUFA date to November 22, 2026.
- Securities-fraud lawsuit announcements remain an overhang.
- Broader indexes are lower, so market sentiment does not directly explain this gain.